Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 41667193
View analysis →In a retrospective cohort of 106 at-risk children, including 40 diagnosed with acute invasive fungal rhinosinusitis, sinus CT showed 83% sensitivity, 97% specificity, and an AUC of 0.90, but missed seven cases, often involving the middle turbinate.
The evidence supports CT as a clinically useful but insufficiently sensitive diagnostic tool; by inference, maintaining nasal endoscopy when suspicion remains despite a negative CT could reduce missed or delayed AIFRS diagnosis in immunocompromised children, although improved treatment outcomes were not evaluated.
In a sex-balanced juvenile rat model, methotrexate produced memory impairments and CSF changes involving one-carbon and transsulfuration metabolites, plasmalogens, and phosphatidylcholines.
The study directly supports an association between methotrexate exposure, altered CSF metabolism, and later memory deficits in juvenile rats; it is reasonable but unproven to hypothesize that these pathways could yield biomarkers or targets for preventing methotrexate-associated cognitive toxicity.
In a retrospective analysis of 5,393 outpatient notes from 1,661 pediatric patients with NF1 at two tertiary programs, the study found substantial variation and longitudinal incompleteness in documentation of core NF1 features and developed a standardized clinical lexicon mapped to existing terminology standards.
The evidence supports standardized NF1 terminology as a way to improve EHR phenotyping and data harmonization; it is reasonable but unproven to infer that this could improve surveillance, trial identification, and real-world evidence generation, with no direct evidence here of treatment efficacy or improved patient outcomes.
This report describes two children with suprasellar mixed germ cell tumors who developed symptomatic tumor enlargement despite falling AFP and β-HCG during chemotherapy, with resection demonstrating mature teratoma consistent with intracranial growing teratoma syndrome.
The cases provide clinical and histopathologic evidence that falling tumor markers can coexist with enlarging mature teratoma; they support, but do not establish, the hypothesis that prompt surgical evaluation and selected early resection during clinical or radiologic progression may relieve mass effect and possibly limit morbidity.
In 138 adolescent and young adult cancer patients receiving anthracyclines, the FADS2-region variant rs97384 was associated with greater odds of reduced skeletal muscle density at follow-up, with additional regional loci also showing associations.
The study provides observational evidence that FADS2-region variants may help identify anthracycline-treated AYA patients at increased risk of early skeletal muscle loss; it remains an untested inference that genotype-guided surveillance, nutrition, or exercise interventions would prevent muscle loss or improve clinical outcomes.
Integrated institutional, bulk-RNA, and single-cell analyses associated TIGIT expression in pediatric B-ALL with CD8+ T-cell and NK-cell exhaustion-related transcriptional features, suppressed antigen-presentation and interferon pathways, and preliminary disease discrimination.
The evidence supports an association between TIGIT expression and exhaustion-related immune signatures in a subset of pediatric B-ALL; it is reasonable but unproven to hypothesize that TIGIT could serve as a biomarker or therapeutic checkpoint target, pending protein-level, functional, and interventional validation.
This multicenter retrospective cohort of 130 children with genetically confirmed Noonan syndrome found frequent structural MRI abnormalities, including brain tumors in 12.3% and Chiari I malformation in 10.7%, with some imaging findings associated with neurological manifestations and interval progression documented in a subset.
The evidence supports MRI as a potentially useful assessment tool in selected children with Noonan syndrome; it is reasonable but unproven to hypothesize that risk-adapted imaging surveillance could enable earlier management of tumors or progressive cranio-cervical abnormalities and improve outcomes.
In a single-center retrospective cohort of 66 children referred with systemic juvenile idiopathic arthritis, 33 carried TNFRSF1A variants and, after genetic assessment and biologic treatment adjustments, were reported to achieve remission with fewer drug switches among those treated after testing.
The record supports an association between early TNFRSF1A testing and fewer biologic-drug switches in this selected autoinflammatory cohort; it suggests—but does not establish—that genotype-informed selection of IL-1, IL-6, or TNF-directed therapy could improve treatment efficiency, with no evidence presented for a pediatric-cancer application.
In baseline data from 935 adults with decompensated cirrhosis and/or hepatocellular carcinoma in the prospective multicenter PAL LIVER trial, FACT-Hep correlated with PROMIS-29 and captured liver disease-specific quality-of-life impairment associated particularly with decompensation and clinical severity.
The record supports FACT-Hep as a clinically relevant patient-reported measure in adults with advanced liver disease; it can be inferred—but is not tested here—that incorporating it into supportive-care trials or symptom monitoring could help identify burdens such as those associated with ascites or hepatic encephalopathy and guide interventions aimed at improving quality of life.
This review synthesizes epidemiology, manifestations, diagnostic approaches, treatment regimens, complications, and prevention of miliary tuberculosis, including CNS-directed therapy, drug-resistant disease, TB-IRIS management, and BCG protection in children.
The supplied review supports established antimicrobial, corticosteroid, diagnostic, and vaccination strategies for miliary tuberculosis; it is reasonable—but untested here—to infer that heightened recognition and optimized diagnosis could benefit immunocompromised pediatric oncology patients, while no cancer-specific therapeutic strategy is evaluated.
In a multicenter cross-sectional cohort of 87 anti-TNF-treated Crohn’s disease patients aged 1–22 years, lower CD64 biomarkers and slower infliximab clearance were associated with endoscopic healing, while anti-TNF trough concentrations were not.
The study provides associative evidence that infliximab clearance and CD64-based pharmacodynamic biomarkers may distinguish patients with endoscopic healing; if prospectively validated, these measures could potentially guide anti-TNF dose escalation versus switching therapy, but no oncology application or clinical benefit from biomarker-guided treatment was tested.
Using SEER and Optum electronic health record data from 2017–2021, the study applied five candidate anthropometric or diagnostic-code criteria to 26,855 children with cancer and found that estimated cachexia prevalence and incidence varied substantially by definition, age, and cancer type.
The study provides observational evidence for a framework to identify potential pediatric cancer cachexia; it is reasonable but unproven to infer that validated consensus criteria could enable earlier nutritional or supportive-care intervention and improve research stratification, as no treatment effect or clinical outcome benefit was tested.
